4-苯乙基-哌嗪-1-基胺 | 34924-96-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-苯乙基-哌嗪-1-基胺
• 英文名称: 4-phenethylpiperazin-1-amine
• 英文别名: 4-phenethyl-piperazin-1-ylamine；4-(2-phenylethyl)piperazin-1-amine
• CAS: 34924-96-4
• 化学式: C₁₂H₁₉N₃
• 分子量: 205.303
• InChiKey: KAHOOFLESLALQF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  32.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-苯乙基-哌嗪-1-基胺 、 2,4-二羟基苯甲醛 以 甲苯 为溶剂， 以148.5 mg的产率得到(E)-4-((4-phenethylpiperazin-1-ylimino)methyl)benzene-1,3-diol
  参考文献：
  名称：

  Structure–activity studies in the development of a hydrazone based inhibitor of adipose-triglyceride lipase (ATGL)

  摘要：

  Adipose triglyceride lipase (ATGL) catalyzes the degradation of cellular triacylglycerol stores and strongly determines the concentration of circulating fatty acids (FAs). High serum FA levels are causally linked to the development of insulin resistance and impaired glucose tolerance, which eventually progresses to overt type 2 diabetes. ATGL-specific inhibitors could be used to lower circulating FAs, which can counteract the development of insulin resistance. In this article, we report about structure-activity relationship (SAR) studies of small molecule inhibitors of ATGL based on a hydrazone chemotype. The SAR indicated that the binding pocket of ATGL requests rather linear compounds without bulky substituents. The best inhibitor showed an IC50 = 10 mu M in an assay with COS7-cell lysate overexpressing murine ATGL. (C) 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

  DOI：

  10.1016/j.bmc.2015.02.051

文献信息

• [EN] APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS<br/>[FR] INHIBITEURS DE KINASE 1 DE RÉGULATION DE SIGNAL D'APOPTOSE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2009123986A1

  公开（公告）日：2009-10-08

  The present invention relates to apoptosis signal-regulating kinase 1 ("ASK1") inhibiting compounds of the formula (I); wherein the variables are as defined herein. The invention also relates to pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.

  本发明涉及具有以下结构的凋亡信号调节激酶1（"ASK1"）抑制化合物（I）；其中变量如本文所定义。该发明还涉及包含这些化合物的药物组合物、试剂盒和制造品；用于制备这些化合物的有用中间体和方法；以及使用这些化合物的方法。
• Cricchio; Arioli; Lancini, Farmaco, Edizione Scientifica, 1975, vol. 30, # 8, p. 605 - 619
  作者：Cricchio、Arioli、Lancini

  DOI：——

  日期：——
• KONSTANTINOVA, RUMYANA GEORGIEVA;ZIKOLOVA, SVETLANA STOYANOVA;STEFANOVA, +
  作者：KONSTANTINOVA, RUMYANA GEORGIEVA、ZIKOLOVA, SVETLANA STOYANOVA、STEFANOVA, +

  DOI：——

  日期：——
• 20-Deoxyrosaramicin derivatives, process for their preparation and pharmaceutical compositions containing them
  申请人：SCHERING CORPORATION

  公开号：EP0042570B1

  公开（公告）日：1983-10-19
• US4279896A
  申请人：——

  公开号：US4279896A

  公开（公告）日：1981-07-21